Innovent Reports P-II Clinical Trial Results of Mazdutide (IBI362) for the Treatment of Obesity in Chinese Adults
Shots:
- The P-II study evaluates mazdutide (9mg) vs PBO in a ratio (3:1) in 80 Chinese patients
- The results showed a superior body weight loss, mean percent change in body weight from baseline vs PBO was -15.4% after 24wks. of treatment & treatment difference of the mean change in body weight was -14.7 kg, patients achieved ≥5%/≥10%/≥15%/≥20% weight loss from baseline (81.7%/65.0%/31.7%/21.7%), respectively while no patients in PBO group lost ≥5% of body weight from baseline
- The overall tolerability & safety were favorable, no patients in mazdutide group discontinued treatment due to AEs with no serious AEs. Innovent collaborated with Eli Lilly to develop & commercialize OXM3 (GLP-1R & GCGR dual agonist) in China
Ref: PRNewswire | Image: Innovent
Related News:- Innovent Reports the First Patients Dosing of Mazdutide (IBI362) in the P-III Study (DREAMS-2) for Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
